Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Krüppel-like factor 10 promotes the progression of breast cancer by activating canonical NF-κB signaling.

Created on 15 Sep 2026

Authors

Xue-Wei Jiang, Jing Liu, Mei-Rong Bao, Xiao-Yan Bai, Ran Tao

Published in

iScience. Volume 29. Issue 3. Pages 115015. Mar 20, 2026. Epub Feb 13, 2026.

Abstract

The elevation of NF-κB activity is frequently found in more malignant cancer types; however, the cause of this activation has still been controversial. Here, we showed that KLF10 promoted breast cancer progression by activating the NF-κB cascade. Mechanistically, KLF10 transcriptionally upregulated RELA mRNA expression. ChIP assay further validated the binding of KLF10 to the RELA promoter. Additionally, by interacting with IκBα and promoting its proteasomal degradation, KLF10 facilitated the release and nuclear translocation of p65, thereby activating the NF-κB signaling. The phosphorylated p65 level was dramatically increased upon KLF10 overexpression. Several targets of NF-κB, including TNF, VEGFA, PLAU, MMP9, ICAM1, CCND1, and MYC, were also upregulated by KLF10. In vivo experiments confirmed that KLF10 promoted breast cancer metastasis, with its expression positively correlated with p65 and negatively correlated with IκBα. Overall, our study elucidates a previously unidentified mechanism driving breast cancer progression, wherein the NF-κB signaling is drastically activated.

PMID:
41797918
Bibliographic data and abstract were imported from PubMed on 15 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement